Premium
The effects of triazolam on cerebral blood flow and metabolism in the dog
Author(s) -
Roald O. K.,
Steen P. A.,
Stangland K.,
Michenfelder J. D.
Publication year - 1986
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1986.tb02401.x
Subject(s) - triazolam , medicine , cerebral blood flow , anesthesia , benzodiazepine , receptor
The new benzodiazepine triazolam was given to six initially awake dogs maintained with spinal anaesthesia and mechanical ventilation. Both cerebral blood flow (CBF) and cerebral metabolic rate for O 2 (CMRo 2 ) were significantly reduced after the initial dose of 0.1 mgx kg ‐1 triazolam, and the EEG changed from an awake to a sleep pattern in less than 20 s. CMRO 2 was gradually reduced with increasing doses of triazolam (0.3, 1.0, 10.0 and 30.0 mgx kg ‐1 ) to 76% of control after the final 30 mgx kg ‐1 dose. CBF did not decrease further after the initial dose, and the addition of N 2 O after the final dose did not cause any significant change in CBF or CMRO 2 . The dogs were hemodynamically stable during the study. Small increases in brain lactate and pyruvate levels, but not in the L/P ratio were the only significant changes in brain metabolite levels. Triazolam appears to be a safe and rapidly acting induction agent in the dog.